Search
for
Sort by
Research 30 of 43
- Rapid and Sensitive LC–MS–MS Method for the Simultaneous Estimation of Alfuzosin and Dutasteride in Human Plasma
- Risk factors for intraoperative floppy iris syndrome: a retrospective study
- A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia
- Anaphylactic shock associated with finasteride and terazosin
- The placebo effect and randomized trials: analysis of conventional medicine
- Economic analysis of finasteride: A model-based approach using data from the Proscar long-term efficacy and safety study
- Serenoa Repens (Saw Palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part III
- Efficacy and Safety of Thermobalancing Therapy in Men with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia was Confirmed by Clinical Trial
- The diagnosis and treatment of iron deficiency and its potential relationship to hair loss
- Generic Development of Topical Dermatologic Products: Formulation Development, Process Development, and Testing of Topical Dermatologic Products
- Applications of steroid drugs entrapped in cyclodextrins
- Androgenic and anti-androgenic effects of progesterone derivatives with different halogens as substituents at the C-6 position
- Dermatologic Reactions to Targeted Therapy
- Symptom management in inflammatory bowel disease
- Tales of bugs, delusions of parasitosis, and what to do
- Application of an Enzymatic Method for Identifying Hair Treatments
- The orchestrated network of skin photoaging: From intercellular crosstalk to molecular signaling
- ECLIPTA ALBA: A Review of Pharmacological Activity with Phyto-Constituents
- Computer Based Screening of Selected Phytoconstituents from Cyperus Rotundus Linn. Against 5 α Reductase Enzyme
- MARIO LACOUTURE: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- A fixed-dose combination of finasteride and tadalafil (Entadfi) for BPH.
- Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
- Direct Vasodilators and Sympatholytic Agents
- Ejaculatory dysfunction in the treatment of lower urinary tract symptoms
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia
- The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction
- The adverse effects of commonly used medications on male fertility: a comprehensive review
- Activation of Polyamine Catabolism Profoundly Alters Tissue Polyamine Pools and Affects Hair Growth and Female Fertility in Transgenic Mice Overexpressing Spermidine/SpermineN 1-Acetyltransferase